Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lowered its stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 2.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 486,499 shares of the company’s stock after selling 10,863 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.68% of Zentalis Pharmaceuticals worth $774,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of ZNTL. Wells Fargo & Company MN lifted its position in Zentalis Pharmaceuticals by 26.8% in the fourth quarter. Wells Fargo & Company MN now owns 34,609 shares of the company’s stock valued at $105,000 after buying an additional 7,305 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $68,000. Barclays PLC boosted its stake in shares of Zentalis Pharmaceuticals by 55.7% in the fourth quarter. Barclays PLC now owns 117,395 shares of the company’s stock valued at $355,000 after purchasing an additional 42,000 shares during the period. Voya Investment Management LLC boosted its stake in shares of Zentalis Pharmaceuticals by 14.1% in the fourth quarter. Voya Investment Management LLC now owns 57,017 shares of the company’s stock valued at $173,000 after purchasing an additional 7,058 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Zentalis Pharmaceuticals by 2.2% in the fourth quarter. Northern Trust Corp now owns 484,738 shares of the company’s stock valued at $1,469,000 after purchasing an additional 10,513 shares during the period.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Wells Fargo & Company lowered their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday, August 7th. HC Wainwright raised shares of Zentalis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 7th. Wedbush reissued a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Finally, Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Zentalis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.20.

Zentalis Pharmaceuticals Stock Up 1.8%

Shares of Zentalis Pharmaceuticals stock opened at $1.72 on Wednesday. The firm has a market capitalization of $124.08 million, a P/E ratio of -0.76 and a beta of 1.76. Zentalis Pharmaceuticals, Inc. has a 52 week low of $1.01 and a 52 week high of $5.44. The firm’s 50 day moving average is $1.46 and its two-hundred day moving average is $1.51.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.19. As a group, research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.